RNA Therapeutics and drug delivery Lab
RNA therapeutics are a broad class of RNA-based or RNA-targeting molecules spanning from short antisense oligonucleotides (ONs) to long modified messenger RNA or CRISPR/Cas9 systems. These modalities can be used to manipulate gene expression for therapeutic purposes, for example to induce gene silencing/activation, modulate splicing or direct gene editing. Our research group focuses on the development of aforementioned RNA therapeutics and application in various neurodegenerative, neuromuscular and inflammatory disease models. This line of research is accompanied with development of effective and safe drug delivery technologies to enhance the bioavailability of RNA therapeutics with a goal of facilitating their translation into clinics.
The main lines of our research are:
1. Development of novel antisense oligonucleotide-based compounds for splice switching applications.
2. Development of drug delivery systems and formulation technologies for mRNA- and CRISPR/Cas9-based systems.
3. Programming of drug delivery systems for targeted delivery.
4. Investigate the mechanism of cellular uptake of therapeutic oligonucleotides and drug delivery systems.
5. Study the application of RNA therapeutics and drug delivery systems in vitro and in vivo disease models.
Interested in our research, please contact us directly: [email protected] or [email protected]
Assoc. Prof. Dr. Taavi Lehto, Head of the Lab, group leader ([email protected])
Dr. Helena Sork, group leader ([email protected])
Dr. Tõnis Lehto ([email protected])
Dr. Annely Lorents ([email protected])
Dr. Mattias Hällbrink ([email protected])
Dr. Helena Faust ([email protected])
PhD students:
Rahel Tops ([email protected])
Obedoulaye Boukary ([email protected])
Ausma Ul Hosna Shikha ([email protected])
Iris Robyn Talgre ([email protected])